Anixa Biosciences Inc (ANIX)

$3.43 -0.06 (-1.72%)
Market Cap 118.74M
Revenue (ttm) 0.00
Net Income (ttm) -10.93M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 117,800
Avg Vol 257,754
Day's Range N/A - N/A
Shares Out 34.02M
Stochastic %K 77%
Beta 0.55
Analysts Strong Sell
Price Target $10.00

Company Profile

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company also engaged in the development of a vaccine against breast cancer; and the development of a vaccine discovery pro...

Industry: Biotechnology
Sector: Healthcare
Phone: 408 708 9808
Address:
3150 Almaden Expressway, Suite 250, San Jose, United States
bioinvestorrr
bioinvestorrr Aug. 19 at 3:06 PM
$ANIX NICE
0 · Reply
Perillo1984
Perillo1984 Aug. 19 at 2:34 PM
$MRNA We can’t forget $ANIX way cheaper why are they getting patents world wide asking for a friend!! Trading at $3 dollars and change!!!
0 · Reply
tommy45
tommy45 Aug. 19 at 11:54 AM
$ANIX bought this stock around june for 2.35 sold yesterday for nice profit . like this stock but looking for a small pull back soon gl guys
0 · Reply
Perillo1984
Perillo1984 Aug. 19 at 11:48 AM
$MRNA Don’t forget $ANIX only trading at $3.44 👏👏👏👏👇👇👇
1 · Reply
bioinvestorrr
bioinvestorrr Aug. 18 at 12:51 PM
$ANIX Dr. Amit Kumar, Chairman and CEO of Anixa, will deliver a presentation that will be available to view beginning at 7:00 AM ET, Friday, September 11, 2026. This is an exciting time for Anixa, with our ovarian cancer CAR-T program now dosing at the highest level evaluated in the trial and our breast cancer vaccine advancing toward Phase 2," said Dr. Kumar. "We look forward to sharing our progress in the coming weeks."
1 · Reply
bioinvestorrr
bioinvestorrr Aug. 17 at 3:58 PM
$ANIX cooking, brewing all the above
0 · Reply
idkmikes57
idkmikes57 Aug. 9 at 4:08 PM
$ANIX Beware could be bull trap. Staying on the sidelines good luck.
0 · Reply
idkmikes57
idkmikes57 Aug. 9 at 3:21 PM
$ANIX headfake!
0 · Reply
SCUBus
SCUBus Aug. 8 at 10:33 AM
$ANIX Range-bound for almost two weeks. Hopefully, forming a base for the next move higher. There have been some block trades of 10,000 shares or more recently on up ticks. Perhaps a sign of institutional buying activity?
1 · Reply
Chasingeeseandbears1507
Chasingeeseandbears1507 Aug. 6 at 12:55 PM
$ANIX awwww don’t like to be called out huh? What a loser lmaoo grow some balls and actually learn how to trade stocks. Stop losing money 🤣🤣🤡🤡
0 · Reply
Latest News on ANIX
Anixa Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Aug 18, 2026, 8:45 AM EDT - 1 day ago

Anixa Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Anixa Biosciences granted Australian patent for breast cancer vaccine

2026-07-14T12:45:52.000Z - 5 weeks ago

Anixa Biosciences granted Australian patent for breast cancer vaccine

Anixa Biosciences Expands Global Patent Portfolio with Australian Patent Acceptance for Breast Cancer Vaccine Technology

Jul 14, 2026, 8:33 AM EDT - 5 weeks ago

Anixa Biosciences Expands Global Patent Portfolio with Australian Patent Acceptance for Breast Cancer Vaccine Technology

Anixa Biosciences, Moffitt Cancer advance ovarian cancer CAR-T trial

2026-07-06T12:41:01.000Z - 6 weeks ago

Anixa Biosciences, Moffitt Cancer advance ovarian cancer CAR-T trial

Anixa Biosciences and Moffitt Cancer Center Advance Ovarian Cancer CAR-T Clinical Trial to Highest Dose Level to Date

Jul 6, 2026, 8:30 AM EDT - 6 weeks ago

Anixa Biosciences and Moffitt Cancer Center Advance Ovarian Cancer CAR-T Clinical Trial to Highest Dose Level to Date

Anixa Biosciences assumed with a Buy at D. Boral Capital

2026-06-30T08:55:08.000Z - 7 weeks ago

Anixa Biosciences assumed with a Buy at D. Boral Capital

Anixa Biosciences granted first Korean patent for breast cancer vaccine

2026-06-29T12:50:17.000Z - 7 weeks ago

Anixa Biosciences granted first Korean patent for breast cancer vaccine

Anixa Biosciences Granted First Korean Patent for its Breast Cancer Vaccine, Extending Global Protection Through 2040

Jun 29, 2026, 8:45 AM EDT - 7 weeks ago

Anixa Biosciences Granted First Korean Patent for its Breast Cancer Vaccine, Extending Global Protection Through 2040

Anixa Biosciences reports results from two clinical-stage immunotherapy programs

2026-06-26T13:15:20.000Z - 7 weeks ago

Anixa Biosciences reports results from two clinical-stage immunotherapy programs

Anixa Biosciences Reports Positive Data from Completed Breast Cancer Vaccine Phase 1 Trial and Positive Survival Observations from Ongoing CAR-T Phase 1 Trial at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium

Jun 26, 2026, 9:10 AM EDT - 7 weeks ago

Anixa Biosciences Reports Positive Data from Completed Breast Cancer Vaccine Phase 1 Trial and Positive Survival Observations from Ongoing CAR-T Phase 1 Trial at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium

Anixa Biosciences Announces Presentations of Two Clinical-Stage Immunotherapy Programs at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium

Jun 11, 2026, 9:05 AM EDT - 2 months ago

Anixa Biosciences Announces Presentations of Two Clinical-Stage Immunotherapy Programs at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium

Anixa Biosciences Quarterly report: Q2 2026

Jun 10, 2026, 7:00 AM EDT - 2 months ago

Anixa Biosciences Quarterly report: Q2 2026

Anixa Biosciences Slides: Corporate presentation

Jun 4, 2026, 7:00 AM EDT - 2 months ago

Anixa Biosciences Slides: Corporate presentation

Anixa Biosciences: CIPO issues Notice of Allowance for patent

2026-06-01T14:17:37.000Z - 2 months ago

Anixa Biosciences: CIPO issues Notice of Allowance for patent

Anixa Biosciences Strengthens International Patent Protection for Ovarian Cancer Vaccine Technology with Canadian Notice of Allowance

Jun 1, 2026, 9:00 AM EDT - 2 months ago

Anixa Biosciences Strengthens International Patent Protection for Ovarian Cancer Vaccine Technology with Canadian Notice of Allowance

Anixa Biosciences’ lira-cel shows positive survival data in ovarian cancer

2026-05-11T14:20:49.000Z - 3 months ago

Anixa Biosciences’ lira-cel shows positive survival data in ovarian cancer

Anixa Biosciences Reports Updated Positive Survival Observations from Ongoing Phase 1 Trial of Lira-cel Ovarian Cancer CAR-T Therapy

May 11, 2026, 8:55 AM EDT - 3 months ago

Anixa Biosciences Reports Updated Positive Survival Observations from Ongoing Phase 1 Trial of Lira-cel Ovarian Cancer CAR-T Therapy

Anixa Biosciences Interview to Air on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV

May 1, 2026, 9:15 AM EDT - 3 months ago

Anixa Biosciences Interview to Air on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV

Anixa Biosciences awarded patent for breast cancer vaccine in Mexico

2026-04-29T13:17:16.000Z - 4 months ago

Anixa Biosciences awarded patent for breast cancer vaccine in Mexico

Anixa Biosciences Announces Issuance of Mexican Patent Covering Breast Cancer Vaccine Technology

Apr 29, 2026, 9:10 AM EDT - 4 months ago

Anixa Biosciences Announces Issuance of Mexican Patent Covering Breast Cancer Vaccine Technology

Anixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy at the International Society for Cell & Gene Therapy 2026 Annual Meeting

Apr 22, 2026, 8:45 AM EDT - 4 months ago

Anixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy at the International Society for Cell & Gene Therapy 2026 Annual Meeting

Anixa Biosciences Transcript: Water Tower Research Insights Conference

Apr 14, 2026, 12:30 PM EDT - 4 months ago

Anixa Biosciences Transcript: Water Tower Research Insights Conference

Anixa Biosciences Slides: Corporate presentation

Apr 14, 2026, 7:00 AM EDT - 4 months ago

Anixa Biosciences Slides: Corporate presentation

Anixa Biosciences to Participate in RedChip's Biotech Resurgence: Platforms and Pipelines of Today's Innovators Conference on April 16, 2026

Apr 9, 2026, 9:05 AM EDT - 4 months ago

Anixa Biosciences to Participate in RedChip's Biotech Resurgence: Platforms and Pipelines of Today's Innovators Conference on April 16, 2026

Anixa Biosciences to Participate in Water Tower Research Insights Conference on April 14, 2026

Apr 7, 2026, 8:55 AM EDT - 4 months ago

Anixa Biosciences to Participate in Water Tower Research Insights Conference on April 14, 2026

Anixa Biosciences CEO Featured on Smart Money Circle Interview Highlighting Advances in Cancer Immunotherapy Programs

Apr 6, 2026, 9:10 AM EDT - 4 months ago

Anixa Biosciences CEO Featured on Smart Money Circle Interview Highlighting Advances in Cancer Immunotherapy Programs

Anixa Biosciences announces agreement with Cytovance Biologics

2026-04-01T12:59:01.000Z - 5 months ago

Anixa Biosciences announces agreement with Cytovance Biologics

Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing

Apr 1, 2026, 8:50 AM EDT - 5 months ago

Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing

Anixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy Clinical Trial at the Society of Gynecologic Oncology Annual Meeting on Women's Cancer

Mar 30, 2026, 9:05 AM EDT - 5 months ago

Anixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy Clinical Trial at the Society of Gynecologic Oncology Annual Meeting on Women's Cancer

Anixa Biosciences Featured on Water Tower Research Healthcare Happenings Podcast

Mar 12, 2026, 10:38 AM EDT - 5 months ago

Anixa Biosciences Featured on Water Tower Research Healthcare Happenings Podcast

Anixa Biosciences Transcript: AGM 2026

Mar 10, 2026, 1:00 PM EDT - 5 months ago

Anixa Biosciences Transcript: AGM 2026

Anixa Biosciences Slides: FY 2026

Mar 10, 2026, 1:00 PM EDT - 5 months ago

Anixa Biosciences Slides: FY 2026

Anixa Biosciences Slides: Corporate presentation

Mar 10, 2026, 7:00 AM EDT - 5 months ago

Anixa Biosciences Slides: Corporate presentation

Anixa Biosciences says Korean MOIP issues Notice of Allowance for new patent

2026-03-09T12:36:09.000Z - 5 months ago

Anixa Biosciences says Korean MOIP issues Notice of Allowance for new patent

Anixa Biosciences Receives Notice of Allowance from Korean Ministry of Intellectual Property (MOIP) for Patent Covering Breast Cancer Vaccine Technology

Mar 9, 2026, 8:30 AM EDT - 5 months ago

Anixa Biosciences Receives Notice of Allowance from Korean Ministry of Intellectual Property (MOIP) for Patent Covering Breast Cancer Vaccine Technology

Anixa Biosciences Quarterly report: Q1 2026

Mar 9, 2026, 7:00 AM EDT - 5 months ago

Anixa Biosciences Quarterly report: Q1 2026

Anixa Biosciences to Host 2026 Annual Meeting of Stockholders and Provide Corporate Update Highlighting Recent Clinical and Regulatory Progress

Mar 2, 2026, 9:10 AM EST - 6 months ago

Anixa Biosciences to Host 2026 Annual Meeting of Stockholders and Provide Corporate Update Highlighting Recent Clinical and Regulatory Progress

Anixa Biosciences Announces Dr. Jose Conejo-Garcia will Keynote the South Carolina Clinical & Translational Research Institute 2026 Retreat

Feb 23, 2026, 8:55 AM EST - 6 months ago

Anixa Biosciences Announces Dr. Jose Conejo-Garcia will Keynote the South Carolina Clinical & Translational Research Institute 2026 Retreat

Anixa Biosciences Transcript: Fireside chat

Feb 10, 2026, 11:00 AM EST - 6 months ago

Anixa Biosciences Transcript: Fireside chat

Anixa Biosciences Press release: Fireside chat

Feb 10, 2026, 11:00 AM EST - 6 months ago

Anixa Biosciences Press release: Fireside chat

Anixa provides update on Phase 1 ovarian cancer CAR-T clinical trial

2026-02-09T13:05:35.000Z - 6 months ago

Anixa provides update on Phase 1 ovarian cancer CAR-T clinical trial

Anixa Biosciences Reports Encouraging Patient Survival Observations in Ovarian Cancer CAR-T Trial; Achieves Regulatory Approval Enabling Major Dose Escalation

Feb 9, 2026, 8:00 AM EST - 6 months ago

Anixa Biosciences Reports Encouraging Patient Survival Observations in Ovarian Cancer CAR-T Trial; Achieves Regulatory Approval Enabling Major Dose Escalation

Anixa Biosciences Slides: Corporate presentation

Feb 7, 2026, 6:00 AM EST - 6 months ago

Anixa Biosciences Slides: Corporate presentation

Anixa Biosciences receives USAN Council approval for novel CAR-T therapy name

2026-02-02T14:10:54.000Z - 7 months ago

Anixa Biosciences receives USAN Council approval for novel CAR-T therapy name

Anixa Biosciences Secures United States Adopted Names Council Approval of Non-Proprietary Name for its CAR-T Therapy, a Key Step Toward Future Commercialization

Feb 2, 2026, 9:00 AM EST - 7 months ago

Anixa Biosciences Secures United States Adopted Names Council Approval of Non-Proprietary Name for its CAR-T Therapy, a Key Step Toward Future Commercialization

Anixa Biosciences Proxy statement: Proxy Filing

Jan 28, 2026, 7:00 AM EST - 7 months ago

Anixa Biosciences Proxy statement: Proxy Filing

Anixa Biosciences granted patent for breast cancer vaccine technology in Mexico

2026-01-27T13:36:37.000Z - 7 months ago

Anixa Biosciences granted patent for breast cancer vaccine technology in Mexico

Anixa Biosciences Receives Notice of Allowance from Mexican Institute of Industrial Property (IMPI) for Patent Covering Breast Cancer Vaccine Technology

Jan 27, 2026, 8:30 AM EST - 7 months ago

Anixa Biosciences Receives Notice of Allowance from Mexican Institute of Industrial Property (IMPI) for Patent Covering Breast Cancer Vaccine Technology

Water Tower Research Publishes Initiation of Coverage Report on Anixa Biosciences, Inc., “Anixa's T-Cell Innovations Show Breakthrough Potential in Solid Tumors”

Jan 21, 2026, 3:54 PM EST - 7 months ago

Water Tower Research Publishes Initiation of Coverage Report on Anixa Biosciences, Inc., “Anixa's T-Cell Innovations Show Breakthrough Potential in Solid Tumors”

Anixa Biosciences Slides: Investor presentation

Jan 16, 2026, 7:00 AM EST - 7 months ago

Anixa Biosciences Slides: Investor presentation

Anixa Biosciences Annual report: Q4 2025

Jan 12, 2026, 7:00 AM EST - 7 months ago

Anixa Biosciences Annual report: Q4 2025

Anixa Biosciences Transcript: Water Tower Research Fireside Chat Series

Dec 15, 2025, 1:00 PM EST - 8 months ago

Anixa Biosciences Transcript: Water Tower Research Fireside Chat Series

Anixa announces transfer of IND for breast cancer vaccine from Cleveland Clinic

2025-12-15T13:51:02.000Z - 8 months ago

Anixa announces transfer of IND for breast cancer vaccine from Cleveland Clinic

Anixa Biosciences Announces Transfer of IND for Breast Cancer Vaccine from Cleveland Clinic

Dec 15, 2025, 8:45 AM EST - 8 months ago

Anixa Biosciences Announces Transfer of IND for Breast Cancer Vaccine from Cleveland Clinic

Anixa Biosciences says all primary endpoints met in breast cancer vaccine trial

2025-12-11T23:05:21.000Z - 8 months ago

Anixa Biosciences says all primary endpoints met in breast cancer vaccine trial

Anixa Biosciences Announces Positive Phase 1 Data for Investigational Breast Cancer Vaccine; Primary Endpoints Were Met and Immune Response Observed in 74% of Participants

Dec 11, 2025, 6:02 PM EST - 8 months ago

Anixa Biosciences Announces Positive Phase 1 Data for Investigational Breast Cancer Vaccine; Primary Endpoints Were Met and Immune Response Observed in 74% of Participants

Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Monday, December 15, 2025

Dec 10, 2025, 9:00 AM EST - 9 months ago

Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Monday, December 15, 2025

Anixa Biosciences’ CAR-T therapy granted WHO approval of non-proprietary name

2025-11-17T13:20:42.000Z - 9 months ago

Anixa Biosciences’ CAR-T therapy granted WHO approval of non-proprietary name

Anixa Biosciences Announces World Health Organization (WHO) Approval of International Non-Proprietary Name for its CAR-T Therapy, Marking a Key Milestone Toward Global Recognition and Future Commercialization

Nov 17, 2025, 8:15 AM EST - 9 months ago

Anixa Biosciences Announces World Health Organization (WHO) Approval of International Non-Proprietary Name for its CAR-T Therapy, Marking a Key Milestone Toward Global Recognition and Future Commercialization

Anixa Biosciences Slides: Corporate Presentation

Nov 17, 2025, 7:00 AM EST - 9 months ago

Anixa Biosciences Slides: Corporate Presentation

Water Tower Research Issues Statement Regarding Technical Interruption During Anixa Biosciences Fireside Chat

Nov 12, 2025, 11:00 AM EST - 9 months ago

Water Tower Research Issues Statement Regarding Technical Interruption During Anixa Biosciences Fireside Chat

Anixa Biosciences awarded patent covering breast cancer vaccine technology

2025-11-12T14:05:48.000Z - 10 months ago

Anixa Biosciences awarded patent covering breast cancer vaccine technology

Anixa Biosciences Awarded Key U.S. Patent Expanding Breast Cancer Vaccine IP Protection into 2040s

Nov 12, 2025, 9:00 AM EST - 10 months ago

Anixa Biosciences Awarded Key U.S. Patent Expanding Breast Cancer Vaccine IP Protection into 2040s

Anixa Biosciences Transcript: Fireside Chat

Nov 11, 2025, 2:00 PM EST - 10 months ago

Anixa Biosciences Transcript: Fireside Chat

Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Tuesday, November 11, 2025

Nov 10, 2025, 10:30 AM EST - 10 months ago

Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Tuesday, November 11, 2025

Anixa Biosciences executes data transfer with Cleveland Clinic

2025-11-05T14:01:35.000Z - 10 months ago

Anixa Biosciences executes data transfer with Cleveland Clinic

Anixa Biosciences Announces Execution of Data Transfer Agreement with Cleveland Clinic

Nov 5, 2025, 8:55 AM EST - 10 months ago

Anixa Biosciences Announces Execution of Data Transfer Agreement with Cleveland Clinic

Anixa Biosciences to Present at the Spartan Capital Securities Second Annual Investor Conference

Oct 23, 2025, 8:45 AM EDT - 10 months ago

Anixa Biosciences to Present at the Spartan Capital Securities Second Annual Investor Conference

Anixa awarded patent in China covering breast cancer vaccine technology

2025-10-20T12:30:48.000Z - 10 months ago

Anixa awarded patent in China covering breast cancer vaccine technology

Anixa Biosciences Announces Issuance of Chinese Patent Covering Breast Cancer Vaccine Technology

Oct 20, 2025, 8:25 AM EDT - 10 months ago

Anixa Biosciences Announces Issuance of Chinese Patent Covering Breast Cancer Vaccine Technology

Anixa Biosciences completes patient visit in breast cancer vaccine trial

2025-10-07T12:35:32.000Z - 11 months ago

Anixa Biosciences completes patient visit in breast cancer vaccine trial

Anixa Biosciences Announces Completion of Final Patient Visit in Breast Cancer Vaccine Clinical Trial

Oct 7, 2025, 8:30 AM EDT - 11 months ago

Anixa Biosciences Announces Completion of Final Patient Visit in Breast Cancer Vaccine Clinical Trial

Cleveland Clinic to Present Final Results of Phase 1 Clinical Trial for Anixa Biosciences' Breast Cancer Vaccine at 2025 San Antonio Breast Cancer Symposium

Sep 22, 2025, 8:05 AM EDT - 11 months ago

Cleveland Clinic to Present Final Results of Phase 1 Clinical Trial for Anixa Biosciences' Breast Cancer Vaccine at 2025 San Antonio Breast Cancer Symposium

Anixa Biosciences Registration statement: Registration Filing

Sep 10, 2025, 8:00 AM EDT - 1 year ago

Anixa Biosciences Registration statement: Registration Filing

Anixa Biosciences Quarterly report: Q3 2025

Sep 10, 2025, 7:00 AM EDT - 1 year ago

Anixa Biosciences Quarterly report: Q3 2025

Anixa Biosciences Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 9, 2025, 10:30 AM EDT - 1 year ago

Anixa Biosciences Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Anixa Biosciences and Moffitt Cancer Center Complete Dosing of Fourth Cohort in Ovarian Cancer CAR-T Clinical Trial; Multiple Patients Surpassing Median Expected Survival

Sep 8, 2025, 8:00 AM EDT - 1 year ago

Anixa Biosciences and Moffitt Cancer Center Complete Dosing of Fourth Cohort in Ovarian Cancer CAR-T Clinical Trial; Multiple Patients Surpassing Median Expected Survival

Anixa Biosciences Announces Time Change for Presentation at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 2, 2025, 8:54 AM EDT - 1 year ago

Anixa Biosciences Announces Time Change for Presentation at the H.C. Wainwright 27th Annual Global Investment Conference

Anixa Biosciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 25, 2025, 9:13 AM EDT - 1 year ago

Anixa Biosciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Anixa Biosciences Receives Notice of Allowance from Chinese National Intellectual Property Administration for Patent Covering Breast Cancer Vaccine Technology

Aug 20, 2025, 8:37 AM EDT - 1 year ago

Anixa Biosciences Receives Notice of Allowance from Chinese National Intellectual Property Administration for Patent Covering Breast Cancer Vaccine Technology

Anixa Biosciences Announces Treatment of Second Patient in Fourth Cohort of Ovarian Cancer CAR-T Clinical Trial

Aug 18, 2025, 9:00 AM EDT - 1 year ago

Anixa Biosciences Announces Treatment of Second Patient in Fourth Cohort of Ovarian Cancer CAR-T Clinical Trial

Anixa Biosciences Announces Issuance of Additional U.S. Patent for CAR-T Technology

Aug 12, 2025, 8:05 AM EDT - 1 year ago

Anixa Biosciences Announces Issuance of Additional U.S. Patent for CAR-T Technology

Anixa Biosciences Announces Dr. Robert Wenham will speak about Immunotherapy in surviving Ovarian Cancer at the 13th Annual Ovarcoming Cancer Conference

Aug 8, 2025, 9:15 AM EDT - 1 year ago

Anixa Biosciences Announces Dr. Robert Wenham will speak about Immunotherapy in surviving Ovarian Cancer at the 13th Annual Ovarcoming Cancer Conference

Anixa Biosciences Announces Commencement of US FDA Approved IND Transfer to Support Upcoming Phase 2 Breast Cancer Vaccine Trial

Aug 4, 2025, 8:45 AM EDT - 1 year ago

Anixa Biosciences Announces Commencement of US FDA Approved IND Transfer to Support Upcoming Phase 2 Breast Cancer Vaccine Trial

Anixa Biosciences Receives Notice of Allowance from Canadian Intellectual Property Office for Patent Covering Breast Cancer Vaccine Technology

Jul 30, 2025, 8:15 AM EDT - 1 year ago

Anixa Biosciences Receives Notice of Allowance from Canadian Intellectual Property Office for Patent Covering Breast Cancer Vaccine Technology

Anixa Biosciences Awarded New U.S. Patent Extending Breast Cancer Vaccine IP Protection into 2040s

Jul 24, 2025, 8:00 AM EDT - 1 year ago

Anixa Biosciences Awarded New U.S. Patent Extending Breast Cancer Vaccine IP Protection into 2040s

Anixa Biosciences Announces Issuance of Additional U.S. Patent for Ovarian Cancer Vaccine Technology

Jul 9, 2025, 8:00 AM EDT - 1 year ago

Anixa Biosciences Announces Issuance of Additional U.S. Patent for Ovarian Cancer Vaccine Technology

Anixa Biosciences Transcript: Status Update

Jun 26, 2025, 2:00 PM EDT - 1 year ago

Anixa Biosciences Transcript: Status Update

Anixa Biosciences Initiates Dosing in Fourth Cohort in its Ovarian Cancer CAR-T Clinical Trial

Jun 23, 2025, 8:00 AM EDT - 1 year ago

Anixa Biosciences Initiates Dosing in Fourth Cohort in its Ovarian Cancer CAR-T Clinical Trial

Anixa Biosciences to Host an Investor Webcast on June 26, 2025

Jun 20, 2025, 7:30 AM EDT - 1 year ago

Anixa Biosciences to Host an Investor Webcast on June 26, 2025

Anixa Biosciences' Breast Cancer Vaccine Receives National News Coverage

Jun 10, 2025, 7:00 AM EDT - 1 year ago

Anixa Biosciences' Breast Cancer Vaccine Receives National News Coverage

bioinvestorrr
bioinvestorrr Aug. 19 at 3:06 PM
$ANIX NICE
0 · Reply
Perillo1984
Perillo1984 Aug. 19 at 2:34 PM
$MRNA We can’t forget $ANIX way cheaper why are they getting patents world wide asking for a friend!! Trading at $3 dollars and change!!!
0 · Reply
tommy45
tommy45 Aug. 19 at 11:54 AM
$ANIX bought this stock around june for 2.35 sold yesterday for nice profit . like this stock but looking for a small pull back soon gl guys
0 · Reply
Perillo1984
Perillo1984 Aug. 19 at 11:48 AM
$MRNA Don’t forget $ANIX only trading at $3.44 👏👏👏👏👇👇👇
1 · Reply
bioinvestorrr
bioinvestorrr Aug. 18 at 12:51 PM
$ANIX Dr. Amit Kumar, Chairman and CEO of Anixa, will deliver a presentation that will be available to view beginning at 7:00 AM ET, Friday, September 11, 2026. This is an exciting time for Anixa, with our ovarian cancer CAR-T program now dosing at the highest level evaluated in the trial and our breast cancer vaccine advancing toward Phase 2," said Dr. Kumar. "We look forward to sharing our progress in the coming weeks."
1 · Reply
bioinvestorrr
bioinvestorrr Aug. 17 at 3:58 PM
$ANIX cooking, brewing all the above
0 · Reply
idkmikes57
idkmikes57 Aug. 9 at 4:08 PM
$ANIX Beware could be bull trap. Staying on the sidelines good luck.
0 · Reply
idkmikes57
idkmikes57 Aug. 9 at 3:21 PM
$ANIX headfake!
0 · Reply
SCUBus
SCUBus Aug. 8 at 10:33 AM
$ANIX Range-bound for almost two weeks. Hopefully, forming a base for the next move higher. There have been some block trades of 10,000 shares or more recently on up ticks. Perhaps a sign of institutional buying activity?
1 · Reply
Chasingeeseandbears1507
Chasingeeseandbears1507 Aug. 6 at 12:55 PM
$ANIX awwww don’t like to be called out huh? What a loser lmaoo grow some balls and actually learn how to trade stocks. Stop losing money 🤣🤣🤡🤡
0 · Reply
drweinerdog1
drweinerdog1 Aug. 6 at 12:50 PM
$ANIX as I was saying very childish people on here
0 · Reply
Stocktradexxx
Stocktradexxx Aug. 3 at 4:30 PM
$ANIX Good to see additional insider buying from CEO Dr. Kumar -https://ir.anixa.com/sec-filings/content/0001493152-26-035751/ownership.html
0 · Reply
CEOBuysDisclosures
CEOBuysDisclosures Aug. 3 at 2:50 PM
$ANIX CEO purchased 5,000 shares at $3.47 for a total of $17,350. KUMAR AMIT now owns 657,000 shares. https://ceo-buys.com
0 · Reply
bioinvestorrr
bioinvestorrr Aug. 3 at 1:57 PM
$ANIX CEO picked up another 5k shares on friday at $3.47. Now owns almost 660k shares
0 · Reply
SCUBus
SCUBus Aug. 2 at 1:01 AM
$ANIX Hopefully just some consolidation around the $3.50 level before moving higher.
0 · Reply
SCUBus
SCUBus Jul. 31 at 12:00 AM
$ANIX Still going up ^^^^^^
0 · Reply
SCUBus
SCUBus Jul. 30 at 1:02 AM
$ANIX Still in the uptrend channel...
0 · Reply
SCUBus
SCUBus Jul. 29 at 12:33 AM
$ANIX Still in the Uptrend Channel Technically Speaking...
0 · Reply
nsiebers2011
nsiebers2011 Jul. 28 at 5:07 PM
$ANIX CEO Amit Kumar disclosed another open-market purchase in a Form 4 filed today — 5,000 shares at $3.44 on 7/27. That's his fifth purchase this month, 21,188 shares total, lifting his direct stake to 652,000. All open-market, none under a 10b5-1 plan. Filing: https://www.sec.gov/Archives/edgar/data/715446/000149315226034952/xslF345X06/ownership.xml
0 · Reply
CEOBuysDisclosures
CEOBuysDisclosures Jul. 28 at 4:25 PM
$ANIX CEO purchased 5,000 shares at $3.44 for a total of $17,200. KUMAR AMIT now owns 652,000 shares. https://ceo-buys.com
0 · Reply
kubota2323
kubota2323 Jul. 28 at 4:09 PM
$ANIX added a few bags.
0 · Reply
tyrus6
tyrus6 Jul. 28 at 2:49 PM
$ANIX Relentless confidence in his company producing a worldwide breast cancer vaccine on display.
0 · Reply